Michele Scrofani, Vice President
HQ Specialty Pharma, LLC
201.857.8290
Paramus, NJ, April 15, 2014 – HQ Specialty Pharma and its collaborating partner, WelGrace Research Group, have received tentative approval on its 505(b)(2) application for Esmolol Hydrochloride Premixed Injection, which references Brevibloc® Injection. The product will be available in two presentations—Esmolol Hydrochloride Premixed Injection 2500 mg/250 mL and Esmolol Hydrochloride DOUBLE STRENGTH Premixed Injection 2000 mg/100 mL in single-dose dual-port bags. Esmolol Premixed Injection will be marketed by WG Critical Care, LLC.
According to IMS, for the 12 months ending 2013, the US market for Brevibloc is approximately $43 million.
About HQ Specialty Pharma, LLC
HQ Specialty Pharma is a privately held specialty pharmaceutical company headquartered in Paramus, New Jersey. A global organization, the HQ Specialty Pharma product pipeline includes a number of innovative, proprietary treatments for human health, and products for animal health.
About WelGrace Research Group
WelGrace Research, headquartered in Lindenhurst, Illinois, is a global horticultural and pharmaceutical specialty company that develops a proprietary portfolio of innovative products for the global markets.
About WG Critical Care, LLC
WG Critical Care, LLC is a fully integrated pharmaceutical company headquartered in Paramus, New Jersey. WGCC’s focus is to provide the hospital and specialty markets with a reliable supply of critical care products.
Brevibloc is a trademark of Baxter International Inc., or its subsidiaries.